Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Lysine Specific Histone Demethylase 1A - Pipeline Review, H2 2017'; Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. 

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Lysine-specific histone demethylase 1A (KDM1A) also known as lysine (K)-specific demethylase 1A (LSD1) is a protein in encoded by the KDM1A gene. LSD1 specifically demethylates mono- or dimethylated dimethylated histone H3 lysine4 (H3K4) and H3 lysine 9 (H3K9) via a redox process. LSD1 played an important role in a broad spectrum of biological processes, including cell proliferation, adipogenesis, spermatogenesis, chromosome segregation and embryonic development. 

The report 'Lysine Specific Histone Demethylase 1A - Pipeline Review, H2 2017' outlays comprehensive information on the Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Other Diseases, Immunology, Infectious Disease and Metabolic Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Small-Cell Lung Cancer, Ewing Sarcoma, Myelodysplastic Syndrome, Alzheimer's Disease, Breast Cancer, Orphan Diseases, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Promyelocytic Leukemia, Autoimmune Disorders, Dementia, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Huntington Disease, Leukemias, Lymphoma, Melanoma, Metastatic Breast Cancer, Multiple Sclerosis, Myelofibrosis, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, Obesity, Parkinson's Disease, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Solid Tumor, Type 2 Diabetes and Viral Infections.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)
- The report reviews Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Overview 8
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 14
Products under Development by Universities/Institutes 18
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Assessment 20
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Companies Involved in Therapeutics Development 24
4SC AG 24
Beactica AB 24
Celgene Corp 25
GlaxoSmithKline Plc 25
Incyte Corp 26
Mirati Therapeutics Inc 27
Oryzon Genomics SA 27
Takeda Pharmaceutical Co Ltd 28
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Drug Profiles 29
4SC-202 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CC-90011 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Drugs to Inhibit KDM1A and PRKCQ for Metastatic Breast Cancer - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GSK-2879552 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
IMG-7289 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
INCB-59872 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ORY-2001 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ORY-3001 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
RASP-201 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
RN-1 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Inhibit LSD1 for Small Cell Lung Cancer and Acute Myelocytic Leukemia - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Inhibit LSD-1 for Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules to Inhibit LSD1 for Alzheimer's Disease, Oncology and Viral Infections - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Inhibit LSD1 for Glioblastoma Multiforme - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Inhibit LSD1 for Obesity and Type 2 Diabetes - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SP-2509 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
SP-2577 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Synthetic Peptide to Inhibit LSD-1 for Oncology - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
T-3775440 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Dormant Products 54
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Discontinued Products 56
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Product Development Milestones 57
Featured News & Press Releases 57
Sep 19, 2017: Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis 57
Jul 24, 2017: ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer's Association International Conference (AAIC-2017) 57
Jul 19, 2017: Imago BioSciences Doses First Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome 58
Apr 24, 2017: ORYZON Announces New Grant from Alzheimer's Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug 59
Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 60
Apr 03, 2017: ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases 60
Feb 27, 2017: ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017 61
Feb 20, 2017: ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA 63
Jan 30, 2017: Oryzon Genomics Will Present ORY-2001 at Keystone Symposia on Epigenetics and Human Disease 63
Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria 64
Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 65
Jan 05, 2017: Mirati Therapeutics Provides Update On Cancer Pre-Clinical Program 65
Nov 08, 2016: Imago BioSciences Enrolls First Patient in Phase 1/2 Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome 66
Sep 12, 2016: Oryzon to Present ORY-2001 Preclinical Efficacy Data in Multiple Sclerosis Animal Model at ECTRIMS-2016 Annual Meeting 66
Jul 27, 2016: Oryzon Initiates Multiple Ascending Dose Cohorts in ORY-2001 Phase 1 Clinical Trial 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Number of Products under Investigation by Universities/Institutes, H2 2017 18
Products under Investigation by Universities/Institutes, H2 2017 19
Number of Products by Stage and Mechanism of Actions, H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 21
Number of Products by Stage and Molecule Type, H2 2017 23
Pipeline by 4SC AG, H2 2017 24
Pipeline by Beactica AB, H2 2017 25
Pipeline by Celgene Corp, H2 2017 25
Pipeline by GlaxoSmithKline Plc, H2 2017 26
Pipeline by Incyte Corp, H2 2017 26
Pipeline by Mirati Therapeutics Inc, H2 2017 27
Pipeline by Oryzon Genomics SA, H2 2017 27
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 28
Dormant Products, H2 2017 54
Dormant Products, H2 2017 (Contd..1), H2 2017 55
Discontinued Products, H2 2017 56